Head-to-head evidence
Paliperidone palmitate (Erzofri) vs Risperidone (QUAR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
In this trial, paliperidone palmitate (INVEGA SUSTENNA) served as the reference comparator against which an investigational competitor formulation, LY03010, was measured for pharmacokinetics; the study was open-label with no blinding, and no results have been posted.
Risperidone (QUAR)
Developed by Laboratorios Farmacéuticos Rovi, S.A.
NCT06276361 · Phase 1 · completed
A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Erzofri)'s landscape · Risperidone (QUAR)'s landscape